Soft tissue procedures using negative pressure
Advanced dressing systems with layered manifold structures enhance lymphatic circulation and tissue healing by applying negative pressure therapy, addressing the limitations of existing wound care systems.
Patent Information
- Application Number
- JP2021504262
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-01
- Filing Date
- 2019-07-30
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2039-07-30
AI Technical Summary
Existing negative pressure therapy systems for wound care lack improvements in treatment components and processes, which can hinder effective tissue healing and circulation enhancement.
The development of advanced dressing systems incorporating layered manifold structures with varying stiffness and materials, such as felted and reticulated polyurethane foams, along with apertured silicone and fenestrated films, to promote negative pressure therapy and enhance lymphatic circulation.
The new dressing systems improve tissue healing by increasing lymphatic circulation and reducing swelling, providing effective treatment for curved tissue sites like the chest, shoulder, arm, leg, or ankle joint, and reducing post-operative complications.
Smart Images

Figure 0007579238000003 
Figure 0007579238000004 
Figure 0007579238000005
Abstract
Description
[Technical field]
[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 713,353, entitled "SOFT-TISSUE TREATMENT WITH NEGATIVE PRESSURE," filed August 1, 2018, which is incorporated by reference herein for all purposes.
[0002] The present disclosure relates generally to tissue treatment systems and, more particularly, but not by way of limitation, to devices and systems for treating tissue using negative pressure. [Background technology]
[0003] Clinical studies and clinical practice have shown that reducing pressure proximal to a tissue site can enhance and accelerate the growth of new tissue at that tissue site. The applications of this phenomenon are numerous, but have proven particularly advantageous for treating wounds. Regardless of the etiology of the wound, whether trauma, surgery, or otherwise, proper care of the wound is important with respect to outcome. Treatment of wounds or other tissues using reduced pressure is sometimes commonly referred to as "negative pressure therapy," but is also known by other names, including, for example, "negative pressure wound therapy," "reduced pressure therapy," "vacuum therapy," "negative pressure wound therapy," and "topical negative pressure." Negative pressure therapy can provide a number of benefits, including epithelial and subcutaneous tissue migration, improved blood flow, and microdeformation of tissue at the wound site. Collectively, these benefits can promote the development of granulation tissue and reduce healing time.
[0004] While the clinical benefits of negative pressure therapy are widely known, improvements in the systems, components, and processes of treatment can benefit healthcare providers and patients. Summary of the Invention
[0005] Novel and useful systems, devices, and methods for treating tissue in a negative pressure therapy environment are set forth in the accompanying claims. Example embodiments are also provided to enable those skilled in the art to make and use the claimed subject matter.
[0006] In some exemplary embodiments, a dressing for treating tissue may include a cuff designed to form a wrap around a limb, such as a leg or arm. Some examples of the dressing may be constructed using a felted polyurethane foam laminated to a reticulated polyurethane foam. The felted foam may form the outer layer, and the reticulated foam may form the patient interface of the core. The circumferentially stiffer felted foam may effectively form a stronger shell, which may allow the softer core to collapse under negative pressure to provide a load-relieving effect on the wound and surrounding tissue. The dressing may further include one or more of a perforated silicone, fabric, or fenestrated film over the core in some examples. The fabric or fenestrated film may inhibit granulation formation, especially when used over an incision site. The dressing may further include an adhesive-backed breathable polyurethane film drape and an air connection to a negative pressure source.
[0007] Moreover, in some exemplary embodiments, a device for promoting circulation through a subcutaneous lymphatic network may include a first manifold layer, a second manifold layer adjacent to the first manifold layer, and a cover layer adjacent to the second manifold layer. The first manifold layer may have a first stiffness and the second manifold layer may have a second stiffness greater than the first stiffness. In some embodiments, the device may further include a fluid interface configured to fluidly couple at least one of the first manifold layer and the second manifold layer to a fluid conduit through the cover layer. The fluid conduit may be coupled or configured to be coupled to a negative pressure source.
[0008] In more detailed exemplary embodiments, the first manifold layer may include or consist of open cell foam and the second manifold layer may include or consist of felted open cell foam.
[0009] In some exemplary embodiments, the device may include one or more additional layers. For example, the device may include a layer adapted to inhibit tissue growth into the first manifold layer, such as a fenestrated polymeric film. Additionally or alternatively, the device may include an immobilization layer, such as a layer of perforated silicone.
[0010] In some exemplary embodiments, the device may include a manifold layer and a cover layer coupled to the manifold layer. The manifold layer may have a first thickness and a first stiffness, and the cover layer may have a second thickness greater than the first thickness and a second stiffness greater than the first stiffness. The fluid interface may be configured to fluidly couple the manifold layer to the fluid conduit through the cover layer. In some examples, the cover layer may include closed cell foam.
[0011] In some exemplary embodiments, devices according to the present disclosure can be used to treat a tissue site using negative pressure, including treatment of soft tissue proximal to the tissue site. The tissue site can be a curved tissue site, such as a chest, shoulder, arm, leg, knee joint, or ankle joint. The tissue site can include an incision in some examples.
[0012] In some exemplary embodiments, a method of treating a tissue site includes applying a first manifold layer, a second manifold layer, and a cover layer over the tissue site, fluidly coupling a negative pressure source to at least one of the first manifold layer and the second manifold layer through the cover layer, and applying negative pressure from the negative pressure source to the second manifold layer, where the first manifold layer has a first thickness and a first stiffness, and the second manifold layer has a second thickness greater than the first thickness and a second stiffness greater than the first stiffness. This method of treatment, in some examples, may promote circulation through the subcutaneous lymphatic network.
[0013] In some exemplary embodiments, a device for promoting circulation through a subcutaneous lymphatic network may include a manifold layer and a support layer adjacent to the manifold layer. The manifold layer may have a first stiffness and the support layer may have a second stiffness greater than the first stiffness. The fluid interface may be configured to fluidly couple at least one of the manifold layer and the support layer to a fluid conduit.
[0014] In some exemplary embodiments, a device for promoting circulation through a subcutaneous lymphatic network may include a manifold layer and a support layer adjacent to the manifold layer. The manifold layer may have a first stiffness of about 800 g force to about 1000 g force. The support layer may have a second stiffness of about 800 g force to about 3000 g force. The fluid interface may be configured to fluidly couple at least one of the manifold layer and the support layer to a fluid conduit.
[0015] In another exemplary embodiment, a method of treating a tissue site includes applying a manifold layer, a support layer, and a cover over the tissue site, fluidly coupling a negative pressure source to at least one of the manifold layer and the support layer through the cover layer, and applying negative pressure from the negative pressure source to the manifold layer, where the manifold layer has a first thickness and a first stiffness, and the support layer has a second thickness and a second stiffness, the second thickness being less than the first thickness. This method of treatment, in some examples, may promote circulation through the subcutaneous lymphatic network.
[0016] In some exemplary embodiments, the test model may include a body having a first end and a second end, a structural member extending through the body from the first end to the second end, and one or more channels extending through the body from the first end to the second end, which may be used to simulate circulation through the subcutaneous lymphatic network.
[0017] The objects, advantages and preferred modes of making and using the claimed subject matter can be best understood by referring to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments. [Brief description of the drawings]
[0018] [Figure 1] FIG. 1 is a block diagram of an exemplary embodiment of a treatment system capable of providing negative pressure treatment in accordance with the present disclosure.
[0019] [Diagram 2] 2 is a graph showing further details of an exemplary pressure control mode that may be associated with some embodiments of the treatment system of FIG. 1.
[0020] [Diagram 3] 13A-13C are graphs showing further details that may be associated with another exemplary pressure control mode in some embodiments of the treatment system of FIG.
[0021] [Figure 4]FIG. 2 is a perspective view of one example of a dressing that may be associated with some embodiments of the treatment system of FIG. 1.
[0022] [Diagram 5] 1. FIG. 2 is a perspective view of another exemplary configuration of a dressing that may be associated with some embodiments of the treatment system of FIG.
[0023] [Figure 6A] 6 is a schematic cross-sectional view of the dressing of FIG. 5 when wrapped to form a cuff or wrap around an appendage. [Figure 6B] 6 is a schematic cross-sectional view of the dressing of FIG. 5 when wrapped to form a cuff or wrap around an appendage.
[0024] [Figure 7] FIG. 1 is an exploded view of one embodiment of a test model.
[0025] [Figure 8] FIG. 8 is an end view of one embodiment of the body of the test model of FIG. 7.
[0026] [Figure 9] FIG. 13 is a perspective view of another embodiment of a test model.
[0027] [Figure 10] FIG. 13 is an end view of another embodiment of the body of the test model.
[0028] [Figure 11] 8 is a table of measurements taken during testing using the test model of FIG. 7.
[0029] [Figure 12] 8 is a table of measurements taken during another test using the test model of FIG. 7.
[0030] [Figure 13] 1. FIG. 2 is a perspective view of another exemplary configuration of a dressing that may be associated with some embodiments of the treatment system of FIG.
[0031] [Figure 14A] 14 is a schematic cross-sectional view of the dressing of FIG. 13 when wrapped to form a cuff or wrap around an appendage. [Figure 14B] 14 is a schematic cross-sectional view of the dressing of FIG. 13 when wrapped to form a cuff or wrap around an appendage.
[0032] [Figure 15] FIG. 14 is a perspective view of the dressing of FIG. 13 when wrapped to form a cuff or wrap around an appendage.
[0033] [Figure 16] 14 is a schematic diagram of one example of a test setup for testing the exemplary configuration of the dressing of FIG. 13 using the test model of FIG. 7.
[0034] [Figure 17] 17 is a flow chart illustrating a method of testing an exemplary configuration of the dressing of FIG. 13 using the test setup of FIG. 16.
[0035] [Figure 18A] 17 is a table of material properties and performance data for an exemplary configuration of the dressing of FIG. 13 using the test setup of FIG. 16. [Figure 18B] 17 is a table of material properties and performance data for an exemplary configuration of the dressing of FIG. 13 using the test setup of FIG. 16.
[0036] [Figure 19] 17 is a bar graph of performance data for an exemplary configuration of the dressing of FIG. 13 using the test setup of FIG. 16.
[0037] [Figure 20] 17 is a plot of performance data for an exemplary configuration of the dressing of FIG. 13 using the test setup of FIG. 16. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] The following description of exemplary embodiments provides information to enable one of ordinary skill in the art to make and use the claimed subject matter, but may omit certain details already known in the art. Thus, the following detailed description is to be construed as illustrative and not limiting.
[0039] FIG. 1 is a block diagram of an exemplary embodiment of a treatment system 100 capable of providing negative pressure therapy to a tissue site in accordance with the present disclosure.
[0040] The term "tissue site" in this context broadly refers to a wound, defect, or other treatment target located on or within tissue, including, but not limited to, bone tissue, adipose tissue, muscle tissue, nerve tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendon, or ligament. Wounds may include, for example, chronic, acute, traumatic, subacute, and dehisced wounds, partial thickness burns, ulcers (such as diabetic ulcers, pressure ulcers, or venous insufficiency ulcers), flap wounds, and transplanted tissue. The term "tissue site" may also refer to any area of tissue, not necessarily a wound or defect, but instead where it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to the tissue site to grow additional tissue that can be harvested and transplanted.
[0041] Treatment system 100 may include a source or supply of negative pressure, such as negative pressure source 105, and one or more distribution components. The distribution components are preferably removable and may be disposable, reusable, or recyclable. Dressings, such as dressing 110, and fluid containers, such as container 115, are examples of distribution components that may be associated with some embodiments of treatment system 100. As shown in the embodiment of FIG. 1, dressing 110 may include or consist essentially of tissue interface 120, cover 125, or both in some embodiments.
[0042] A fluid conduit is another example of a distribution component. In this context, a "fluid conduit" broadly includes a tube, pipe, hose, conduit, or other structure having one or more lumens or open passages adapted to transport a fluid between two ends. Typically, a tube is an elongated cylindrical structure with some flexibility, but the geometry and stiffness can vary. Furthermore, some fluid conduits may be molded into or otherwise integrally combined with other components. A distribution component may also include or configure an interface or fluid port to facilitate coupling and decoupling of other components. In some embodiments, for example, a dressing interface may facilitate coupling of the fluid conduit to the dressing 110. For example, such a dressing interface may be a SENSAT.RAC™ Pad available from Kinetic Concepts, Inc. of San Antonio, Texas.
[0043] The treatment system 100 may also include a regulator or controller, such as a controller 130. Additionally, the treatment system 100 may include sensors for measuring operating parameters and providing feedback signals indicative of the operating parameters to the controller 130. For example, as shown in FIG. 1, the treatment system 100 may include a first sensor 135 and a second sensor 140 connected to the controller 130.
[0044] Some components of the treatment system 100 may also be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces, that further facilitate treatment. For example, in some embodiments, the negative pressure source 105 may be incorporated within a treatment unit along with the controller 130 and other components.
[0045] In general, the components of the treatment system 100 may be coupled directly or indirectly. For example, the negative pressure source 105 may be directly coupled to the reservoir 115 or indirectly coupled to the dressing 110 via the reservoir 115. The coupling may include fluid coupling, mechanical coupling, thermal coupling, electrical coupling, or chemical coupling (such as chemical coupling), or some combination of couplings depending on the context. For example, the negative pressure source 105 may be electrically coupled to the controller 130 and fluidly coupled to one or more distribution components to provide a fluid pathway to the tissue site. In some embodiments, the components may also be coupled by physical proximity, being integrated into a single structure, or being formed from the same piece of material.
[0046] A negative pressure source, such as negative pressure source 105, can be a reservoir of air at negative pressure or can be a manual or powered device, such as, for example, a vacuum pump, a suction pump, a wall suction port available in many healthcare facilities, or a micropump. "Negative pressure" generally refers to a pressure that is lower than the local ambient pressure, such as the ambient pressure in the local environment outside the sealed treatment environment. In many cases, the local ambient pressure can also be the atmospheric pressure where the tissue site is located. Alternatively, the pressure can be lower than the hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise indicated, pressure values described herein are gauge pressures. References to an increase in negative pressure typically refer to a decrease in absolute pressure, while a decrease in negative pressure typically refers to an increase in absolute pressure. The amount and nature of negative pressure provided by negative pressure source 105 may vary depending on the treatment requirements, but the pressure is typically a low vacuum, also commonly referred to as a rough vacuum, between -5mmHg (-667 Pa) and -500mmHg (-66.7 kPa). A typical treatment range is between -50mmHg (-6.7 kPa) and -300mmHg (-39.9 kPa).
[0047] Container 115 represents a container, canister, pouch, or other storage component that may be used to manage exudate and other fluids drawn from a tissue site. In many circumstances, a rigid container may be preferred or required for fluid collection, storage, and disposal. In other circumstances, fluids may be properly disposed of without being stored in a rigid container, and reusable containers may reduce waste and costs associated with negative pressure therapy.
[0048] A controller, such as controller 130, can be a microprocessor or computer programmed to operate one or more components of the treatment system 100, such as the negative pressure source 105. For example, in some embodiments, the controller 130 can be a microcontroller, which generally comprises an integrated circuit including a processor core and memory, programmed to directly or indirectly control one or more operating parameters of the treatment system 100. The operating parameters can include, for example, the power applied to the negative pressure source 105, the pressure generated by the negative pressure source 105, or the pressure delivered to the tissue interface 120. The controller 130 is also preferably configured to receive one or more input signals, such as feedback signals, and is programmed to modify one or more operating parameters based on the input signals.
[0049] A sensor, such as the first sensor 135 and the second sensor 140, may be any device operable to detect or measure a physical phenomenon or physical property and generally provide a signal indicative of the detected or measured phenomenon or property. For example, the first sensor 135 and the second sensor 140 may be configured to measure one or more operating parameters of the treatment system 100. In some embodiments, the first sensor 135 may be a transducer configured to measure the pressure in the air path and convert the measurement into a signal indicative of the measured pressure. In some embodiments, for example, the first sensor 135 may be a piezoresistive strain gauge. The second sensor 140 may optionally measure an operating parameter of the negative pressure source 105, such as a voltage or current, in some embodiments. Preferably, the signals from the first sensor 135 and the second sensor 140 are suitable as input signals to the controller 130, although in some embodiments some signal conditioning may be appropriate. For example, the signals may need to be filtered or amplified before they can be processed by the controller 130. Typically, the signals are electrical signals, but may be represented in other forms, such as optical signals.
[0050] The tissue interface 120 may generally be adapted to partially or completely contact a tissue site. The tissue interface 120 may take many forms and may have many sizes, shapes, or thicknesses depending on various factors, such as the type of procedure being performed or the nature and size of the tissue site. For example, the size and shape of the tissue interface 120 may be adapted to the contours of a deep, irregularly shaped tissue site. Any or all of the surfaces of the tissue interface 120 may have an uneven, rough, or jagged profile.
[0051] In some embodiments, the tissue interface 120 may include or consist essentially of a manifold. A manifold in this context may include or consist essentially of a means for collecting or distributing fluid across the tissue interface 120 under pressure. For example, the manifold may be adapted to receive negative pressure from a source and distribute the negative pressure across the tissue interface 120 via a number of openings, which may have the effect of collecting fluid across the tissue site and drawing the fluid towards the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate delivery of fluid across the tissue site.
[0052] In some exemplary embodiments, the manifold may include multiple pathways that may be interconnected to improve fluid distribution or collection. In some exemplary embodiments, the manifold may include or consist essentially of a porous material having interconnected fluid pathways. Examples of suitable porous materials that may be adapted to form interconnected fluid pathways (e.g., channels) may include cellular foams, including open-cell foams such as reticulated foams; porous tissue assemblies; and other porous materials, such as gauze or felt mats, that generally include pores, edges, and / or walls. Liquids, gels, and other foams may also include, or be cured to include, openings and fluid pathways. In some embodiments, the manifold may also or alternatively include protrusions that form interconnected fluid pathways. For example, the manifold may be molded to provide surface protrusions that define the interconnected fluid pathways.
[0053] The tissue interface 120 can be either hydrophobic or hydrophilic. In embodiments where the tissue interface 120 can be hydrophilic, the tissue interface 120 can also wick fluid away from the tissue site while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 120 can draw fluid away from the tissue site by capillary flow or other wicking mechanisms. One example of a hydrophilic material that may be suitable is a polyvinyl alcohol open cell foam, such as VACWHITEFOAM™ dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams can include those made from polyethers. Other foams that can exhibit hydrophilic properties include hydrophobic foams that have been treated or coated to impart hydrophilic properties.
[0054] In some embodiments, the tissue interface 120 can be constructed from a bioresorbable material. Suitable bioresorbable materials can include, but are not limited to, a polymer blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymer blend can also include, but is not limited to, polycarbonate, polyfumarate, and caprolactone. The tissue interface 120 can also function as a scaffold for new cell growth, or a scaffold material can be used in conjunction with the tissue interface 120 to promote cell growth. A scaffold is generally a substance or structure used to enhance or promote cell growth or tissue formation, such as a three-dimensional porous structure that provides a template for cell growth. Examples of scaffold materials include calcium phosphate, collagen, PLA / PGA, coral hydroxyapatite, carbonate, or engineered allograft materials.
[0055] In some embodiments, the cover 125 may provide a barrier against bacteria and protection from physical trauma. The cover 125 may also be constructed from a material capable of reducing evaporative loss and providing a fluid seal between two components or between two environments, such as between a treatment environment and a local external environment. The cover 125 may include or consist of, for example, an elastomeric film or membrane capable of providing an appropriate seal to maintain negative pressure at the tissue site for a given source of negative pressure. The cover 125 may have a high moisture-vapor transmission rate (MVTR) in some applications. For example, the MVTR may be at least 250 grams per square meter per 24 hours measured using an upright cup technique according to the Upright Cup Method of ASTM E96 / E96M at 38° C. and 10% relative humidity (RH). In some embodiments, an MVTR of up to 5,000 grams per square meter per 24 hours may provide effective breathability and mechanical properties.
[0056] In some exemplary embodiments, the cover 125 can be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquids. Such drapes typically have a thickness in the range of 25-50 micrometers. For permeable materials, the permeability should generally be low enough so that the desired negative pressure can be maintained. The cover 125 can include, for example, one or more of the following materials: polyurethanes (PU), such as hydrophilic polyurethanes, cellulose derivatives, hydrophilic polyamides, polyvinyl alcohols, polyvinylpyrrolidones, hydrophilic acrylics, silicones, such as hydrophilic silicone elastomers, natural rubber, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, ethylene vinyl acetate (EVA), copolyesters, and polyether block polyamide copolymers. Such materials are commercially available, for example, Tegaderm® drapes available from 3M Company, Minneapolis, Minnesota; polyurethane (PU) drapes available from Avery Dennison Corporation, Pasadena, California; polyether block polyamide copolymers (PEBAX), for example, from Arkema SA, Colombes, France; and Inspire 2301 and Inspire 2327 polyurethane films available from Expopack Advanced Coatings, Wrexham, United Kingdom. In some embodiments, the cover 125 is 2600 g / m 2 / INSPIRE 2301, which has a 24 hour MVTR (standing cup technology) and a thickness of approximately 30 micrometers.
[0057] An attachment device can be used to attach the cover 125 to an attachment surface, such as an intact epidermis, a gasket, or another cover. The attachment device can take many forms. For example, the attachment device can be a medically acceptable pressure sensitive adhesive configured to bond the cover 125 to the epidermis surrounding the tissue site. In some embodiments, for example, some or all of the cover 125 can be coated with an adhesive, such as an acrylic adhesive, which can have a coating weight of about 25 to 65 grams per square meter (gsm). In some embodiments, a thicker adhesive, or combination of adhesives, can be applied to improve sealing and reduce leakage. Other exemplary embodiments of the attachment device can include double-sided tape, glue, hydrocolloid, hydrogel, silicone gel, or organogel.
[0058] In operation, the tissue interface 120 can be disposed within, on, over, or otherwise proximate to the tissue site. For example, if the tissue site is a wound, the tissue interface 120 can partially or completely occlude or be disposed over the wound. A cover 125 can be disposed over the tissue interface 120 and sealed to an attachment surface proximate the tissue site. For example, the cover 125 can be sealed to the intact epidermis surrounding the tissue site. Thus, the dressing 110 can provide a sealed treatment environment proximate to the tissue site that is substantially isolated from the external environment, and the negative pressure source 105 can reduce pressure in the sealed treatment environment.
[0059] The fluid dynamics of using a negative pressure source to reduce pressure in another component or location, such as within a sealed treatment environment, can be mathematically complex, however, the basic principles of fluid dynamics applicable to negative pressure therapy are generally well known to those skilled in the art, and the process of reducing pressure can be illustratively described herein as "delivering," "distributing," or "generating" negative pressure, for example.
[0060] Generally, exudate and other fluids flow along a fluid path toward a lower pressure. Thus, the term "downstream" refers to a location in the fluid path that is relatively closer to a negative pressure source or farther away from a positive pressure source. Conversely, the term "upstream" refers to a location that is farther away from a negative pressure source or closer to a positive pressure source. Similarly, in such a frame of reference, it may be convenient to describe certain features in terms of a fluid "inlet" or "outlet". This orientation is generally assumed for purposes of describing various features and components herein. However, the fluid path may also be reversed in some applications, such as by replacing a negative pressure source with a positive pressure source, and this explanatory definition should not be construed as a limiting definition.
[0061] In a sealed treatment environment, negative pressure applied across the tissue site via tissue interface 120 can induce macro- and microstrains in the tissue site. The negative pressure can also remove exudates and other fluids from the tissue site, which can be collected in container 115.
[0062] In some embodiments, the controller 130 can receive and process data from one or more sensors, such as the first sensor 135. The controller 130 can also control the operation of one or more components of the treatment system 100 to manage the pressure delivered to the tissue interface 120. In some embodiments, the controller 130 can include an input for receiving a desired target pressure and can be programmed to process data regarding the setting and input of the target pressure to be applied to the tissue interface 120. In some exemplary embodiments, the target pressure can be a fixed pressure value that is set by an operator as the desired target negative pressure for treatment at the tissue site and then provided as an input to the controller 130. The target pressure can vary from tissue site to tissue site based on the type of tissue forming the tissue site, the type of injury or wound (if any), the medical condition of the patient, and the preferences of the attending physician. After selecting the desired target pressure, the controller 130 can operate the negative pressure source 105 in one or more control modes based on the target pressure and can receive feedback from one or more sensors to maintain the target pressure at the tissue interface 120.
[0063] FIG. 2 is a graph showing further details of an exemplary control mode that may be associated with some embodiments of the controller 130. In some embodiments, the controller 130 may have a continuous pressure mode in which the negative pressure source 105 is operated to provide a constant target negative pressure for the duration of the treatment or until manually deactivated, as shown by lines 205 and 210. Additionally or alternatively, the controller may have an intermittent pressure mode, as shown in the example of FIG. 2. In FIG. 2, the x-axis represents time and the y-axis represents the negative pressure generated by the negative pressure source 105 over time. In the example of FIG. 2, the controller 130 may operate the negative pressure source 105 to cycle between the target pressure and atmospheric pressure. For example, the target pressure may be set to a value of 125 mmHg for a specified period of time (e.g., 5 minutes), as shown by line 205, followed by deactivation for a specified period of time (e.g., 2 minutes), as shown by the gap between solid lines 215 and 220. This cycling process can be repeated by activating the negative pressure source 105, as shown by line 220, which can create a square wave pattern between the target pressure and atmospheric pressure.
[0064] In some exemplary embodiments, the increase in negative pressure from ambient pressure to the target pressure may not be instantaneous. For example, the negative pressure source 105 and dressing 110 may have an initial rise time, as indicated by dashed line 225. The initial rise time may vary depending on the type of dressing and treatment device being used. For example, the initial rise time for one treatment system may range from about 20-30 mmHg / sec, and for another treatment system may range from about 5-10 mmHg / sec. If the treatment system 100 is operating in an intermittent mode, the repetitive rise time, as indicated by solid line 220, may be substantially equal to the initial rise time, as indicated by dashed line 225.
[0065] FIG. 3 is a graph showing further details that may be associated with another exemplary pressure control mode in some embodiments of the treatment system 100. In FIG. 3, the x-axis represents time and the y-axis represents the negative pressure generated by the negative pressure source 105. The target pressure in the example of FIG. 3 may vary over time in a dynamic pressure mode. For example, the target pressure may vary in the form of a triangular waveform with a rise time 305 set at a rate of +25 mmHg / min and a fall time 310 set at -25 mmHg / min, varying between a negative pressure of 50 mmHg and a negative pressure of 125 mmHg. In other embodiments of the treatment system 100, the triangular waveform may vary between a negative pressure of 25 mmHg and a negative pressure of 125 mmHg, with a rise time 305 set at a rate of +30 mmHg / min and a fall time 310 set at -30 mmHg / min.
[0066] In some embodiments, the controller 130 can control or determine a variable target pressure in a dynamic pressure mode, which can vary between a maximum and minimum pressure value that can be set as an operator-defined input as a range of desired negative pressure. The variable target pressure can also be processed and controlled by the controller 130, which can vary the target pressure according to a predetermined waveform, such as a triangular waveform, a sinusoidal waveform, or a sawtooth waveform. In some embodiments, the waveform can be set by the operator as a predetermined or time-varying negative pressure desired for treatment.
[0067] FIG. 4 is a perspective view of an example of the dressing 110 of FIG. 1 showing further details that may be relevant to some embodiments. As shown in the example of FIG. 4, the tissue interface 120 may include two or more layers. In some examples, the tissue interface 120 may include an inner layer that includes or consists essentially of a manifold. The tissue interface 120 may also include an outer layer that includes or consists essentially of a manifold in some examples, and in other examples, the outer layer may include or consist essentially of a medical grade closed cell foam. In some examples, the inner layer may be configured to be positioned between the outer layer and the tissue site. In some examples, the inner layer may be proximal to the tissue site and the outer layer may be distal to the tissue site. In some examples, the inner layer may be in direct contact with the tissue site.
[0068] In the example of FIG. 4, tissue interface 120 includes first manifold layer 405 and second manifold layer 410, which in some embodiments may be curved. In some examples, first manifold layer 405 may be an inner layer and second manifold layer 410 may be an outer layer. In some examples, first manifold layer 405, second manifold layer 410, and cover 125 may be disposed in a laminated relationship with second manifold layer 410 interposed between first manifold layer 405 and cover 125. In some embodiments, cover 125 may be omitted or cover 125 may comprise a suitable closed cell foam. For example, if tissue interface 120 has an outer layer of a suitable closed cell foam, cover 125 may not be necessary. In some embodiments, second manifold layer 410 may be bonded to first manifold layer 405 and cover 125 may be bonded to second manifold layer 410. For example, the second manifold layer 410 can be disposed adjacent to the first manifold layer 405, and the cover 125 can be disposed adjacent to the second manifold layer 410. In some embodiments, the second manifold layer 410 can be laminated to the first manifold layer 405, and the cover 125 can be laminated to the second manifold layer 410.
[0069] In some embodiments, the outer layer can be stiffer than the inner layer. For example, the second manifold layer 410 can be stiffer than the first manifold layer 405. The stiffness of the second manifold layer 410 can be about 4 to about 7 times greater than the stiffness of the first manifold layer 405 in some configurations. In some embodiments, the stiffness of the second manifold layer 410 can be about 5 times greater than the stiffness of the first manifold layer 405. In some embodiments, the stiffness of the first manifold layer 405 and the second manifold layer 410 can be tested using a compressive load deflection test. The compressive load deflection test can be used to measure the force required to compress a sample of material. A 25% compressive load deflection is the force required to compress a sample of material by 25%. A 65% compressive load deflection is the force required to compress a sample of material by 65%. In some embodiments, the first manifold layer 405 can have a stiffness in the range of approximately 0.3 to 0.4 pounds per square inch (25% compressive load deflection) and the second manifold layer 410 can have a stiffness in the range of approximately 1.5 to 2 pounds per square inch (25% compressive load deflection).
[0070] The first manifold layer 405 and the second manifold layer 410 may also have different thicknesses in some embodiments. As shown in FIG. 4, the second manifold layer 410 may be thicker than the first manifold layer 405. For example, the first manifold layer 405 may have a first thickness T1 and the second manifold layer 410 may have a second thickness T2, where T2 may be greater than T1. In some configurations, the thickness T1 may be from about 5 millimeters to about 7 millimeters and T2 may be from about 11 millimeters to about 13 millimeters. In some embodiments, T2 may be about twice T1. For example, the first manifold layer 405 may have a thickness of about 6 millimeters and the second manifold layer 410 may have a thickness of about 12 millimeters.
[0071] In some embodiments, the first manifold layer 405 may include or consist essentially of a reticulated foam with pore size and free volume or open voids that may vary depending on the prescribed treatment needs. For example, a reticulated foam with at least 90% free volume may be suitable for many treatment applications, and a foam with an average pore size in the range of 400-600 micrometers (40-50 pores per inch) may be particularly suitable for some types of treatments. The tensile strength of the first manifold layer 405 may also vary depending on the prescribed treatment needs. The 25% compressive load deflection of the first manifold layer 405 may be at least 0.35 pounds per square inch, and the 65% compressive load deflection may be at least 0.43 pounds per square inch. In some embodiments, the tensile strength of the first manifold layer 405 may be at least 10 pounds per square inch. The first manifold layer 405 may have a tear strength of at least 2.5 pounds per square inch. In some embodiments, the first manifold layer 405 can be a foam comprised of a polyol, such as a polyester or polyether, an isocyanate, such as toluene diisocyanate, and a polymerization modifier, such as an amine or tin compound. In some examples, the first manifold layer 405 can be a reticulated polyurethane foam, such as that found in GRANUFOAM™ dressings or VACVERAFLO™ dressings, both available from Kinetic Concepts, Inc. of San Antonio, Texas.
[0072] The second manifold layer 410 may also include or consist essentially of reticulated foam in some embodiments. For example, the second manifold layer 410 may include or consist essentially of the same material as the first manifold layer 405, and may be felted to increase the stiffness of the second manifold layer 410.
[0073] In some examples, tissue interface 120 may further include a layer adapted to prevent granulation, which may be particularly advantageous when used over an incision site. In some examples, this layer may include a suitable fabric or fenestrated film. In the example of FIG. 4, this layer consists essentially of a film layer 415 having fenestrations 420. Film layer 415 may be disposed adjacent to first manifold layer 405, and in some configurations may be bonded to first manifold layer 405. In some embodiments, film layer 415 may substantially cover one side of first manifold layer 405. Film layer 415 may include or consist essentially of means for controlling or managing fluid flow, means for reducing or preventing tissue growth into first manifold layer 405, or both. In some embodiments, film layer 415 may include or consist essentially of a liquid impermeable elastomeric material. For example, the film layer 415 may include or consist essentially of a polymer film, such as a polyurethane film. In some embodiments, the film layer 415 may include or consist essentially of the same material as the cover 125. The film layer 415 may also have a smooth or matte surface texture in some embodiments. For some applications, a polished or glossy finish, grade B3 or higher according to the SPI (Institute of Plastics Industry) standard, may be particularly advantageous. In some embodiments, the surface height variation may be limited to an acceptable tolerance. For example, the surface of the film layer 415 may have a substantially flat surface with a height variation limited to 0.2 millimeters over one centimeter.
[0074] In some embodiments, the film layer 415 can be hydrophobic. The hydrophobicity of the film layer 415 can vary, but in some embodiments, the film layer 415 can have a contact angle with water of at least 90 degrees. In some embodiments, the film layer 415 can have a contact angle with water of 150 degrees or less. For example, in some embodiments, the contact angle of the film layer 415 can be in the range of at least 90 degrees to about 120 degrees, or at least 120 degrees to 150 degrees. The water contact angle can be measured using any standard device. A manual goniometer can be used to visually estimate the contact angle, but contact angle measuring instruments, among others, often include an integrated system including a horizontal stage, a liquid dropper such as a syringe, a camera, and software designed to more accurately and precisely calculate the contact angle. Non-limiting examples of such integrated systems include the FTÅ125, FTÅ200, FTÅ2000, and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc. of Portsmouth, VA, and the DTA25, DTA30, and DTA100 systems, all commercially available from Kruss GmbH of Hamburg, Germany. Unless otherwise specified, water contact angles herein are measured using deionized distilled water on a horizontal sample surface with a drop applied from a height of 5 cm or less in air at 20-25° C. and 20-50% relative humidity. Contact angles herein represent the average of 5-9 measurements, discarding both the highest and lowest measurements. The hydrophobicity of the film layer 415 can be further enhanced using hydrophobic coatings of other materials, such as silicones and fluorocarbons, such as those coated with liquids or plasma coated.
[0075] The film layer 415 may also be suitable for welding to other layers, including the first manifold layer 405. For example, the film layer 415 may be adapted for welding to polyurethane foam using heat, radio frequency (RF) welding, or other methods for generating heat, such as ultrasonic welding. RF welding may be particularly suitable for more polar materials, such as polyurethanes, polyamides, polyesters, and acrylates. A sacrificial polarity interface may be used to facilitate RF welding of less polar film materials, such as polyethylene.
[0076] The areal density of the film layer 415 may vary depending on the prescribed treatment or application. In some embodiments, an areal density of less than 40 grams per square meter may be suitable, and for some applications, an areal density of about 20-30 grams per square meter may be particularly advantageous.
[0077] In some embodiments, for example, the film layer 415 may include or consist essentially of a hydrophobic polymer, such as a polyethylene film. The simple and inert structure of polyethylene may provide a surface that interacts little, if at all, with biological tissue and fluids, thereby promoting free flow and low adhesion of liquids, which may be particularly advantageous for many applications. Other suitable polymer films include polyurethane, acrylic, polyolefin (such as cyclic olefin copolymers), polyacetate, polyamide, polyester, copolyester, PEBAX block copolymer, thermoplastic elastomer, thermoplastic vulcanizate, polyether, polyvinyl alcohol, polypropylene, polymethylpentene, polycarbonate, styrenic, silicone, fluoropolymer, and acetate. Thicknesses between 20 micrometers and 100 micrometers may be suitable for many applications. The film may be clear, colored, or printed. More polar films suitable for laminating to the polyethylene film include polyamide, copolyester, ionomer, and acrylic. A tie layer, such as ethylene vinyl acetate or modified polyurethane, can be used to aid in bonding between the polyethylene and the polar film. Ethyl methyl acrylate (EMA) film can also have suitable hydrophobic and welding properties for some configurations.
[0078] As shown in the example of FIG. 4, the fenestrations 420 can be distributed uniformly or randomly across the film layer 415. The fenestrations 420 can be bidirectional and pressure responsive. For example, each of the fenestrations 420 can generally include or consist essentially of elastic passages that are normally non-distorting and can expand or open in response to a pressure gradient to substantially reduce the flow of liquid. In some embodiments, the fenestrations 420 can include or consist essentially of perforations in the film layer 415. The perforations can be formed by removing material from the film layer 415. For example, the perforations can be formed by cutting through the film layer 415, which can also deform the edges of the perforations in some embodiments. In the absence of a pressure gradient across the perforations, the passages can be small enough to form a seal or fluid restriction that can substantially reduce or prevent the flow of liquid. Additionally or alternatively, one or more of the fenestrations 420 may be elastomeric valves that are normally closed when unstrained to substantially prevent liquid flow and that can open in response to a pressure gradient. Fenestrations in the film layer 415 may be the preferred valves for some applications.
[0079] FIG. 5 is a perspective view of another exemplary configuration of the dressing 110 of FIG. 1 showing further details that may be relevant to some embodiments. As shown in the example of FIG. 5, the tissue interface 120 may further or alternatively include an adhesive layer 505. In some embodiments, the adhesive layer 505 may substantially cover one side of the first manifold layer 405. The adhesive layer 505 may be formed from a soft, adhesive material, such as a suitable gel material, and may have a substantially flat surface. For example, the adhesive layer 505 may include, but is not limited to, silicone gel, soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrene copolymer gel, foam gel, soft closed cell foam such as polyurethane and polyolefin coated with adhesive, polyurethane, polyolefin, or hydrogenated styrene copolymer. In some embodiments, the adhesive layer 505 may have a thickness of about 200 micrometers (μm) to about 1000 micrometers (μm). In some embodiments, the bonding layer 505 may have a hardness of about 5 Shore OO to about 80 Shore OO. Additionally, the bonding layer 505 may be composed of a hydrophobic or hydrophilic material.
[0080] In some embodiments, the bonding layer 505 can be a hydrophobic coating material. For example, the bonding layer 505 can be formed by coating a material having interstices, such as a woven mesh, a non-woven mesh, a molded mesh, or an extruded mesh, with a hydrophobic material. The hydrophobic material for the coating can be, for example, soft silicone.
[0081] The bonding layer 505 of Figure 5 has apertures 510. The apertures 510 can be formed, for example, by cutting, drilling, or by application of localized RF or ultrasonic energy, or other suitable techniques for forming openings or perforations in the bonding layer 505. The apertures 510 can have a uniform distribution pattern or can be randomly distributed in the bonding layer 505. The apertures 510 can have many shapes including, for example, circles, squares, stars, ellipses, polygons, slits, complex curves, linear shapes, triangles, or any combination of such shapes.
[0082] Each of the openings 510 may have uniform or similar geometric characteristics. For example, in some embodiments, each of the openings 510 may be a circular opening having substantially the same diameter. In some embodiments, each of the openings 510 may have a diameter between about 1 millimeter and about 50 millimeters. In other embodiments, the diameter of each of the openings 510 may be between about 1 millimeter and about 20 millimeters. In other embodiments, the geometric characteristics of the openings 510 may vary. For example, the diameter of the openings 510 may vary depending on the location of the openings 510 within the bonding layer 505.
[0083] In some examples, the bonding layer 505 may be used in combination with the film layer 415. For example, in some embodiments, the film layer 415 may be disposed between the first manifold layer 405 and the bonding layer 505, and at least a portion of the fenestrations 420 and openings 510 may be aligned or registered.
[0084] In some embodiments, one or more layers of the tissue interface 120 can be coextensive. For example, the second manifold layer 410 can be cut flush with the edge of the first manifold layer 405. The cover 125 can also be coextensive with the tissue interface 120, or can be larger to provide a margin for attachment to an attachment device.
[0085] The cover 125, first manifold layer 405, second manifold layer 410, film layer 415, bonding layer 505, or various combinations can be assembled prior to application or at the tissue site or treatment site. In some embodiments, the dressing 110 can be provided as a single composite dressing.
[0086] In use, the tissue interface 120 can be placed within, on, or otherwise proximate to a tissue site, such as an incision and adjacent epidermis. The film layer 415, the bonding layer 505, or both, can be interposed between the first manifold layer 405 and the tissue site, which can substantially reduce or eliminate adverse interactions between the first manifold layer 405 and the tissue site. For example, the bonding layer 505 can be placed over the incision and intact epidermis to prevent direct contact with the first manifold layer 405. The bonding layer 505 can be sufficiently adhesive to hold the dressing 110 in place, but can also allow the dressing 110 to be removed or repositioned without trauma to the tissue site. In some embodiments, if the cover 125 provides a margin around the tissue interface 120, the cover 125 can be attached to the epidermis or another attachment surface to seal the tissue interface 120. Additionally or alternatively, a secondary cover can be used to seal any exposed margins or joints around the tissue interface 120. The negative pressure source 105 can be fluidly coupled to the tissue interface 120 through the cover 125. The dressing 110 can include or be coupled to a fluid interface configured to fluidly couple at least one of the first manifold layer 405 and the second manifold layer 410 to the negative pressure source 105.
[0087] The geometry and dimensions of the tissue interface 120, the cover 125, or both, may be varied to suit a particular application or anatomical structure. For example, the geometry or dimensions of the tissue interface 120 and the cover 125 may be adapted to provide an effective and reliable seal at and around a tissue site against difficult anatomical surfaces, such as the chest, shoulder, elbow, or heel. In some embodiments, the tissue interface 120 and the cover 125 may be configured to be applied to an appendage, such as an arm or a leg, including a joint, such as the knee or ankle.
[0088] 6A and 6B are schematic cross-sectional views of the dressing 110 of FIG. 5 when wrapped to form at least a partial cuff or wrap around a curved tissue site, such as an appendage. FIG. 6A illustrates the dressing 110 without negative pressure applied, and FIG. 6B illustrates the dressing 110 with negative pressure applied. Negative pressure applied through the tissue interface 120 can create a compressive force on the tissue site. As shown in FIG. 6B, the lower stiffness of the first manifold layer 405 allows the first manifold layer 405 to compress more than the second manifold layer 410, which can surprisingly increase perfusion through the soft tissue surrounding the tissue site.
[0089] For example, surprising results were demonstrated by testing one embodiment of the dressing 110 to measure the flow rate through a test apparatus: Four test samples were wrapped around a test model configured to simulate an appendage having bone and soft tissue.
[0090] FIG. 7 is an isometric view of one embodiment of a test model 700. The test model 700 can include a body 705, a first end cap 710, a second end cap 715, and a structural member 720. The body 705 can have a first end 725 and a second end 730. In some embodiments, the body 705 can be cylindrical and can have a diameter ranging from about 25 millimeters to about 160 millimeters. In some embodiments, the body 705 can have a diameter of about 50 millimeters. In some embodiments, the body 705 can have a length from the first end 725 to the second end 730 of about 75 millimeters to about 300 millimeters. In some embodiments, the body 705 can have a length from the first end 725 to the second end 730 of about 150 millimeters. In some embodiments, the body 705 can be constructed of a silicone material. The silicone material can be a soft silicone and can be made to look, feel, and move like living tissue. In some embodiments, the body 705 can be molded from PLATSIL™ Gel-10, available from Polytek Development Corp., having a Shore A hardness of 10+ / -2.
[0091] The body 705 may have one or more channels 735 extending through the body 705 from the first end 725 to the second end 730. The channels 735 may be molded over the length of the body 705 to simulate a lymphatic network through the appendage. In some embodiments, each channel 735 in a population of channels 735 may have the same diameter. In some embodiments, the channels 735 may have different diameters. In some embodiments, the population of channels 735 may have a diameter ranging from about 0.75 millimeters to about 2.0 millimeters. In some embodiments, the population of channels 735 may have a diameter of about 1.6 millimeters.
[0092] The structural member 720 may extend through the body 705 from a first end 725 to a second end 730. In some embodiments, the structural member 720 may be a cylindrical rod having a diameter of about 10 millimeters. In some embodiments, the structural member 720 may be a cylindrical rod having a diameter ranging from about 5 millimeters to about 30 millimeters. The structural member 720 may be a rigid shaft formed of, for example, steel, stainless steel, aluminum, titanium, or other suitable metal or alloy. In some embodiments, the structural member 720 may be a rigid shaft formed of polyvinyl chloride (PVC), polypropylene (PP), polycarbonate (PC), acrylic (PMMA), acetal (polyoxymethylene (POM)), acrylonitrile butadiene styrene (ABS), or other suitable hard plastic. In some embodiments, the body 705 is molded around the structural member 720. The structural member 720 may be located through the center of the body 705. In some embodiments, the structural member 720 may be offset from the center of the body 705. The structural member 720 may simulate bone supporting tissue.
[0093] The first end cap 710 can be coupled to a first end 725 of the body 705, and the second end cap 715 can be coupled to a second end 730 of the body 705. The first end cap 710 and the second end cap 715 can include one or more fittings 740 extending therefrom, respectively. Each fitting 740 can be fluidly coupled to a channel 735 extending through the body 705. The number of fittings 740 in each of the first end cap 710 and the second end cap 715 can be equal to the number of channels 735 in the body 705. As shown in FIG. 7, the fittings 740 can be barbed fittings. In some embodiments, the fittings 740 can be threaded fittings. The fittings 740 are configured to couple the test model 700 to flexible tubing.
[0094] The first end cap 710 and the second end cap 715 may be formed of, for example, steel, stainless steel, aluminum, titanium, or other suitable metals or alloys. In some embodiments, the first end cap 710 and the second end cap 715 may be formed of polyvinyl chloride (PVC), polypropylene (PP), polycarbonate (PC), acrylic (PMMA), acetal (polyoxymethylene (POM)), acrylonitrile butadiene styrene (ABS), or other suitable rigid plastics. The first end cap 710 and the second end cap 715 may be manufactured in a variety of ways, including, but not limited to, 3D printing, injection molding, machining, and casting.
[0095] In some embodiments, the body 705 can be molded around at least a portion of the first end cap 710 and / or the second end cap 715. The first end cap 710 and the second end cap 715 can be coupled to the structural member 720. In some embodiments, the first end cap 710 and the second end cap 715 can be coupled to the structural member 720 by screws 745. In some embodiments, the first end cap 710 and the second end cap 715 can be coupled to the structural member 720 by an adhesive. In some embodiments, the first end cap 710 and the second end cap 715 can be coupled to the structural member 720 by welding. In some embodiments, the first end cap 710, the second end cap 715, and the structural member 720 can be integrally formed.
[0096] In some embodiments, the test model 700 may include soft transitions between the first end cap 710 and the body 705, and between the second end cap 715 and the body 705. The soft transitions may reduce the risk of shearing at the joints between the first end cap 710 and the body 705, and between the second end cap 715 and the body 705. The soft transitions may be provided, for example, by short lengths of silicone tubing to allow for a flexible transition between the population of fittings 740 and the population of channels 735.
[0097] 8 is an end view of body 705 showing further details of one embodiment of test model 700. As shown in FIG. 8, in some embodiments, the population of channels 735 may include a first channel 800 at a depth of 1 millimeter from the surface of body 705, a second channel 805 at a depth of 3 millimeters from the surface of body 705, a third channel 810 at a depth of 7 millimeters from the surface of body 705, and a fourth channel 815 at a depth of 15 millimeters from the surface of body 705. In some embodiments, body 705 may include five or more channels.
[0098] FIG. 9 is an isometric view of another embodiment of the test model 700. As shown in FIG. 9, in some embodiments, the first end cap 710 and the second end cap 715 may each include one or more protrusions 900 extending from the first end cap 710 and the second end cap 715 in a direction away from the fitting 740. Each protrusion 900 may include a cylindrical portion 905 and have a head 910 at an end of the cylindrical portion 905. The head 910 may have a larger diameter than the cylindrical portion 905. In some embodiments, the protrusions 900 may be barbed fittings. Each protrusion 900 may further include a channel 915 that is fluidly coupled with the channel 735 in the body 705 and the fitting 740. The protrusions 900 may be configured to engage the body 705 to align the fitting 740 with the channel 735. The protrusions 900 may also aid in stabilizing the body 705. In some embodiments, the first end cap 710 and the second end cap 715 each include one protrusion 900. In some embodiments, the first end cap 710 and the second end cap 715 each include two or more protrusions 900. In some embodiments, the number of protrusions 900 on each of the first end cap 710 and the second end cap 715 can be equal to the number of channels 735 in the body 705.
[0099] 10 is an end view of body 705 showing further details of one embodiment of test model 700. As shown in FIG. 10, channels 735 can be arranged in a spiral pattern when viewed from first end 725 or second end 730 (not shown). Test model 700 can be scaled to represent larger anatomical structures such as, for example, a human or animal arm, leg, thigh, or torso. For example, test model 700 can have a diameter of about 160 millimeters and a length of about 290 millimeters.
[0100] During testing of sample dressings 110, channels 735 were connected to an air supply with pressure set at a constant rate of 2 centimeters Hg. Airflow measurements were taken with sample dressings applied before and after negative pressure for each individual channel 735 and for all channels 735 combined.
[0101] FIG. 11 is a table of measurements taken during the first test, where Sample 1 illustrates a dressing with similar or similar features to the embodiment of FIG. 5, including an inner manifold layer and a stiffer outer manifold layer. More specifically, Sample 1 was constructed with an inner layer of reticulated foam and an outer layer of reticulated foam that was felted to increase stiffness. Samples 2-4 included various conventional dressing configurations with manifold features that did not have a stiffness differential. FIG. 11 summarizes the results of the test, and surprisingly shows the improved performance of Sample 1 with the stiffer outer layer. The data in FIG. 11 shows the increase in flow rate, in percentage, through the channel 735 of the test model 700 with negative pressure applied compared to when no negative pressure was applied. The asterisks in FIG. 11 indicate that the measured flow rate was outside the range of the measurement device.
[0102] 12 summarizes the results of a second test in which Sample 1 was tested at different pressure levels. These results surprisingly demonstrate that flow rate was increased at lower levels of negative pressure. That is, the flow rate through channel 735 of test model 700 was higher when the negative pressure applied to Sample 1 was −100 mmHg compared to −200 mmHg.
[0103] 13 is a perspective view of another exemplary configuration of the dressing 110 of FIG. 1 showing further details that may be relevant to some embodiments. The tissue interface 120 of the dressing 110 may include a first manifold layer 405, an outer layer, such as a support layer 1300, and a cover 125. In some examples, the first manifold layer 405, the support layer 1300, and the cover 125 may be disposed in a laminated relationship with the support layer 1300 interposed between the first manifold layer 405 and the cover 125. In some embodiments, the cover 125 may be omitted. For example, the cover 125 may not be necessary if the support layer 1300 comprises a material capable of providing a fluid seal, such as, for example, a suitable closed cell foam. In some embodiments, the support layer 1300 may be bonded to the first manifold layer 405, and the cover 125 may be bonded to the support layer 1300. For example, the support layer 1300 can be disposed adjacent to the first manifold layer 405, and the cover 125 can be disposed adjacent to the support layer 1300. In some embodiments, the support layer 1300 can be laminated to the first manifold layer 405, and the cover 125 can be laminated to the support layer 1300.
[0104] In some embodiments, the stiffness of the first manifold layer 405 and the support layer 1300 can be measured using ASTM D6828-02, Standard Test Method for Fabric Stiffness by Blade / Slot Procedure. In some embodiments, the first manifold layer 405 can have a stiffness in the range of about 800 grams force (gf) to about 1000 grams force. In some embodiments, the first manifold layer 405 can have a stiffness of about 910 grams force. In some embodiments, the support layer 1300 can have a stiffness in the range of about 500 grams force to about 3000 grams force. In some embodiments, the support layer 1300 can have a stiffness in the range of about 800 grams force to about 2000 grams force. In some embodiments, the support layer 1300 can have a stiffness in the range of about 1000 grams force to about 2000 grams force. In some embodiments, the support layer 1300 can have a stiffness in the range of about 1200 grams force to about 1500 grams force. In some embodiments, the support layer 1300 may have a stiffness of about 500 g-force or greater. In some embodiments, the support layer 1300 may have a stiffness of about 800 g-force or greater. In some embodiments, the support layer 1300 may have a stiffness of about 1000 g-force or greater. In some embodiments, the support layer 1300 may have a stiffness of about 1200 g-force or greater. In some embodiments, the support layer 1300 may have a stiffness of about 1400 g-force or greater. In some embodiments, the support layer 1300 may have a stiffness of about 725 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 834.75 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 846 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 1220 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 1446 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 1490 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 2326 g-force. In some embodiments, the support layer 1300 may have a stiffness of about 11486 g-force.
[0105] In some examples, the support layer 1300 can be stiffer than the first manifold layer 405. The stiffness of the support layer 1300 can be about 1.3 to about 13 times greater than the stiffness of the first manifold layer 405 in some configurations. In some embodiments, the support layer 1300 can be about 1.3 to about 2.6 times greater than the stiffness of the first manifold layer 405. In some embodiments, the support layer 1300 can be about 1.3 to about 1.7 times greater than the stiffness of the first manifold layer 405. In some embodiments, the support layer 1300 can be about 1.3 to about 1.6 times greater than the stiffness of the first manifold layer 405. In some embodiments, the support layer 1300 can be about 1.6 times greater than the stiffness of the first manifold layer 405.
[0106] The first manifold layer 405 and the support layer 1300 may also have different thicknesses in some embodiments. In some embodiments, the support layer 1300 may be thinner than the first manifold layer 405. For example, the first manifold layer 405 may have a first thickness T1 and the support layer 1300 may have a second thickness T2, where T2 may be less than T1. In some configurations, the thickness T1 may be from about 5 millimeters to about 7 millimeters and T2 may be from about 0.1 millimeters to about 3 millimeters. In some embodiments, the first manifold layer 405 may have a thickness of about 6.35 millimeters and the support layer 1300 may have a thickness of about 1.96 millimeters.
[0107] In some embodiments, the support layer 1300 may include or consist essentially of a closed cell foam. For example, the support layer 1300 may include or consist essentially of a neoprene foam. In some embodiments, the support layer 1300 may include or consist essentially of a knitted fabric. For example, the support layer 1300 may include or consist essentially of a double knit polyester fabric. For example, the support layer 1300 may include or consist essentially of a pique knit polyester fabric. For example, the support layer 1300 may include or consist essentially of a jersey knit blend of about 21% polyester, about 65% nylon, and about 14% spandex. In some embodiments, the support layer 1300 may include or consist essentially of a woven fabric. For example, the support layer 1300 may include or consist essentially of a 1×1 plain weave blend of about 65% polyester and about 35% cotton. For example, the support layer 1300 may include or consist essentially of a 3×1 twill blend of about 65% polyester and about 35% cotton. For example, the support layer 1300 may include or consist essentially of a 1×1 plain weave of polyester coated with polyurethane. In some embodiments, the support layer 1300 may include or consist essentially of a film. For example, the support layer 1300 may include or consist essentially of an 8 gauge polyvinyl chloride film. For example, the support layer 1300 may include or consist essentially of a 16 gauge polyvinyl chloride film. For example, the support layer 1300 may include or consist essentially of a 20 gauge polyvinyl chloride film.In some embodiments, the polyvinyl chloride film can be transparent, translucent, or opaque. In some embodiments, the support layer 1300 can include or consist essentially of a composite film. For example, the support layer 1300 can include or consist essentially of a glass cloth coated with polytetrafluoroethylene (PTFE) resin. In some embodiments, the support layer 1300 can include or consist essentially of a mesh. For example, the support layer 1300 can include or consist essentially of a polyurethane foam grid mesh having a square grid. For example, the support layer 1300 can include or consist essentially of a multifilament nylon PA66 mesh having a square grid. For example, the support layer 1300 can include or consist essentially of a resorcinol formaldehyde latex coated glass mesh having a square grid. In some embodiments, the support layer 1300 may include or consist essentially of a nonwoven material. For example, the support layer 1300 may include or consist essentially of a nonwoven polyester fabric. For example, the support layer 1300 may include or consist essentially of a nonwoven polyester fabric that has been heat pressed at about 375 degrees Fahrenheit for 1 minute. In some embodiments, the support layer 1300 may include or consist essentially of a rubber. For example, the support layer 1300 may include or consist essentially of an acrylonitrile butadiene rubber.
[0108] As further shown in the example of FIG. 13, in some embodiments, the support layer 1300 may have one or more apertures 1305. The apertures 1305 may be formed, for example, by cutting, drilling, or by application of localized RF or ultrasonic energy, or other suitable techniques for forming openings or perforations in the support layer 1300. The apertures 1305 may have a uniform distribution pattern or may be randomly distributed in the support layer 1300. In some embodiments, the apertures 1305 may be arranged across the support layer 1300 such that the apertures 1305 are staggered. For example, the apertures 1305 may be arranged with a triangular pitch. In some embodiments, the apertures 1305 may be arranged across the support layer 1300 such that the apertures 1305 are linearly centered. For example, the apertures 1305 may be arranged with a rectangular pitch. The openings 1305 may have many shapes, including, for example, circles, squares, stars, ovals, polygons, slits, complex curves, linear shapes, triangles, or any combination of such shapes. Each of the openings 1305 may have uniform or similar geometric characteristics. For example, in some embodiments, each of the openings 1305 may be circular openings having substantially the same diameter. In some embodiments, the openings 1305 may be circles having a diameter ranging from about 1 millimeter to about 15 millimeters. In some embodiments, the openings 1305 may be circles having a diameter ranging from about 5 millimeters to about 10 millimeters. In some embodiments, the openings 1305 may be circles having a diameter of about 6.35 millimeters. In other embodiments, the geometric characteristics of the openings 1305 may vary. For example, the diameter of the openings 1305 may vary depending on the location of the openings 1305 within the support layer 1300.
[0109] In some embodiments, the openings 1305 can be arranged across the support layer 1300 at a center-to-center distance or pitch ranging from about 3 millimeters to about 50 millimeters. In some embodiments, the openings 1305 can be arranged across the support layer 1300 at a center-to-center distance or pitch of about 12.7 millimeters. In some embodiments, the openings 1305 can be arranged across the support layer 1300 at a center-to-center distance or pitch of about 25.4 millimeters. The openings 1305 in the support layer 1300 provide an open area in the support layer 1300. The open area is the ratio of the total area of all the openings 1300 to the total area of the support layer 1300. The open area can be expressed as a percentage. For example, for a 25% open area, 25% of the area of the support layer 1300 is open and 75% of the area of the support layer 1300 is closed. In some embodiments, the open area can range from about 3% to about 50%. In some embodiments, the open area can range from about 4% to about 6%. In some embodiments, the open area can range from about 10% to about 30%. In some embodiments, the open area can be less than 50%. In some embodiments, the open area can be about 4.9%. In some embodiments, the open area can be about 5.7%.
[0110] One of the openings 1305 in the support layer 1300 may be fluidly coupled to the opening 1310 in the cover 125 and may have a larger size to accommodate the size of the opening 1310 in the cover 125. The dressing 110 may be coupled to the negative pressure source 105 by a fluid conduit 1315 and a dressing interface 1320. The fluid conduit 1315 may be a flexible tube that may be fluidly coupled at one end to the dressing interface 1320. The dressing interface 1320 may be an elbow-type connector that may be positioned over the opening 1310 in the cover 125 and one or more of the openings 1305 to provide a fluid pathway between the fluid conduit 1315 and the tissue interface 120, as shown in the embodiment of FIG. 13. The one or more openings 1305 may allow negative pressure to be provided to the first manifold layer 405 through the support layer 1300.
[0111] 13, in some embodiments, the dressing 110 may include an adhesive layer 505. Additionally, or alternatively, the dressing 110 may include a film layer 415 (not shown in FIG. 13) disposed between the first manifold layer 405 and the adhesive layer 505.
[0112] 14A and 14B are schematic cross-sectional views of the dressing 110 of FIG. 13 when wrapped to form at least a partial cuff or wrap around a curved tissue site, such as an appendage. FIG. 14A illustrates the dressing 110 without negative pressure applied, and FIG. 14B illustrates the dressing 110 with negative pressure applied. The test model 700 is not shown for purposes of clarity. When negative pressure is not applied, the dressing 110 can have a first inside dimension, such as a first inside diameter (D1). When negative pressure is applied, the dressing 110 can have a second inside dimension, such as a second inside diameter (D2), the second inside dimension being larger than the first inside dimension, such as D2>D1. The increased second inside diameter (D2) is shown in an exaggerated form for illustrative purposes. Negative pressure applied through the tissue interface 120 can create an expansive force on the tissue site. As shown in FIG. 14B, the increased stiffness of the support layer 1300 allows the first manifold layer 405 to collapse outwardly under application of negative pressure to the tissue interface 120, resulting in reduced pressure in the underlying tissue and increased lymphatic flow. The outward collapse of the first manifold layer 405 (as indicated by arrow A in FIG. 14B) pulls the epidermis and underlying tissue outward, opening up vascular and lymphatic pathways, which allows for a higher rate of perfusion through the vascular and lymphatic pathways. Thus, the increased outward pulling force can increase the diameter of the vascular and / or lymphatic pathways, which can increase blood and lymphatic flow through the tissue site. The outward collapse of the first manifold layer 405 under application of negative pressure can surprisingly increase perfusion through the soft tissue surrounding the tissue site. In some embodiments, for example, the dressing 110 can increase simulated lymphatic flow up to five times greater than without the dressing 110.
[0113] Furthermore, as shown in FIG. 14B, when negative pressure is applied to the dressing 110, portions of the cover 125 may be drawn into the openings 1305 in the support layer 1300 toward the first manifold layer 405, thereby forming recesses 1400.
[0114] 15 is an isometric view of the dressing 110 of FIG. 6 shown under application of negative pressure. As shown in FIG. 15, under application of negative pressure, the outline of the opening 1305 may be visible through the cover 125. Furthermore, the recess 1400 formed by the cover 125 being drawn into the opening 1305 may be visible and palpable. The appearance of the outline of the opening through the cover 125 under application of negative pressure may be useful as evidence that negative pressure is being applied to the tissue interface 120. If the outline of the support layer 1300 cannot be discerned through the cover 125 after a certain amount of time after negative pressure has been applied to the dressing 110, this may be an indication of a leak in the dressing 110.
[0115] Surprising results were demonstrated by testing an embodiment of the dressing 110 shown in FIG. 13 to measure the flow rate through the test model 700. Twenty test samples were wrapped around the test model 700.
[0116] 16 is a schematic diagram of a test setup 1600 for measuring flow rates through a test model 700 using various embodiments of the dressing 110 shown in FIG. 13. As shown in FIG. 16, the test setup 1600 includes an air supply 1605, a fluid conduit 1610, a manometer 1615, a filter 1620, an air flow meter 1625, and a manifold 1630 coupled to the test model 700. The fluid conduit 1610 is fluidly coupled to the air supply 1605. The air supply 1605 can supply air to the test model 700 via the fluid conduit 1610, as shown by arrow B. The manometer 1615 can be fluidly coupled to the fluid conduit 1610 downstream of the air supply 1605. The manometer 1615 can be used to measure the pressure of the air in the fluid conduit 1610. A filter 1620 can be fluidly coupled in series with the fluid conduit 1610 downstream of the manometer 1615. The filter 1620 can be used to filter the air before it enters the air flow meter 1625 and the test model 700. The air flow meter 1625 can be fluidly coupled in series with the fluid conduit 1610 downstream of the filter 1620. The air flow meter 1625 can be used to measure the air flow rate through the test model 700. A manifold 1630 can be fluidly coupled in series with the air flow meter 1625. The manifold 1630 can include a number of fluid conduits 1635 similar to the number of channels 735 of the test model 700. The fluid conduits 1635 of the manifold 1630 can be fluidly coupled to a fitting 740 of the test model 700.
[0117] FIG. 17 illustrates a method 1700 of testing an embodiment of the dressing 110 shown in FIG. 13 using the test setup 1600 of FIG. 16. In step 1705, the air supply 1605 is turned on and adjusted to provide a constant air pressure of about 51.7 mmHg (about 1 psi) at a flow rate in the range of about 1.2 liters per minute (lpm) to about 1.5 liters per minute (lpm). This flow rate is set as the free flow rate (FF). In step 1710, the test model 700 is coupled to the manifold 1630 such that the fluid conduit 1635 of the manifold 1630 is fluidly coupled to the fitting 740 of the test model 700. In step 1715, a sample of the dressing 110 is wrapped around the test model 700 and the cover 125 is sealed to the test model 700 to form a sealed space that contains the tissue interface 120. At step 1720, the tissue interface 120 is fluidly coupled to the negative pressure source 105 using the fluid conduit 1315 and the dressing interface 1320. At step 1725, prior to application of negative pressure to the dressing 110, the air flow meter 1625 is used to measure the restricted air flow (RF) through the channel 735 of the test model 700. This restricted air flow (RF) can be recorded. At step 1730, negative pressure is applied to the tissue interface 120 until a target negative pressure in the tissue interface 120 of approximately 100 mmHg is reached. At step 1735, the air flow meter 1625 is used to measure the negative air flow (NPF) through the channel 735 of the test model 700. This negative air flow (NPF) can be recorded. When negative pressure is applied to the dressing 110, the first manifold layer 405 contracts outward, creating a lifting force on the body 705 of the test model 700, resulting in a negative pressure air flow rate (NPF) greater than the restricted flow rate (RF). At step 1740, the negative pressure source 105 is turned off, allowing the pressure inside the dressing 110 to decay to ambient pressure.In some embodiments, steps 1725, 1730, 1735, and 1740 can be repeated (e.g., three or more times) using the same dressing 110, and the values for restricted airflow (RF) and negative airflow (NPF) can be averaged for each sample of dressing 110. Method 1700 can then be repeated for each sample of dressing 110 to be tested.
[0118] For each sample of dressing 110 tested, the measured free flow (RF), restricted air flow (RF), and negative air flow (NPF) can be used to evaluate the performance of the dressing 110. The following formula can be used to compare the performance of samples of dressing 110. A scale factor can be calculated using the following: Scale=FF-RF The difference in flow rate between negative pressure airflow (NPF) and restricted airflow (RF) (Δ flow ) can be calculated using: Δ flow = NPF-RF The rate of increase in flow can be calculated using: TIFF0007579238000001.tif12128 The improvement in flow rate can be calculated using: In some embodiments, the performance of the dressing 110 may be calculated for each channel 735. In some embodiments, the performance of the dressing 110 may be calculated based on flow rates averaged across one or more of the channels 735.
[0119] 18A and 18B are tables of material properties and performance data for an exemplary configuration of the dressing 110 of FIG. 13 using the test setup of FIG. 16. Twenty samples were tested (samples 5-24). Sample 5 dressing 110 included only the first manifold layer 405 and cover 125, with the first manifold layer 405 having a stiffness of 910 grams force, an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm (tested per ASTM D6828-02). 2 18A and 18B. Sample 5 showed a simulated lymphatic flow improvement rate of 1.12%. Sample 5 was used to establish a baseline. Dressings 110 of Samples 6-24 are illustrative of dressings having similar or similar features to the embodiment of FIG. 13, including first manifold layer 405 and support layer 1300. However, for testing purposes, Samples 6-24 included only first manifold layer 405, support layer 1300, and cover 125, with first manifold layer 405 being the same as first manifold layer 405 of Sample 5, and support layer 1300 including various materials having the material descriptions and properties identified in FIGS. 18A and 18B. That is, the material of first manifold layer 405 was held constant for Samples 5-24. 18A and 18B also summarize the results of the study.
[0120] In Sample 6, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 1446 grams force, an average thickness of 1.96 millimeters, a density of 0.11 g / cc, and a mass per unit area of 0.02 g / cm. 2 Sample 6 had a 44.30% improvement in simulated lymphatic flow.
[0121] In Sample 7, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 0.01 g / cm 3 and a stiffness (tested by ASTM D6828-02) of 5.5 grams force, an average thickness of 0.59 millimeters, a density of 0.21 g / cc, and a viscosity of 0.01 g / cm 3 . 2 Sample 7 had a 9.06% improvement in simulated lymphatic flow.
[0122] In Sample 8, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 1.0 g / cm 2 , a stiffness of 40.5 grams force (tested per ASTM D6828-02), an average thickness of 1.06 millimeters, a density of 0.26 g / cc, and a viscosity of 0.03 g / cm 3 . 2The fabric comprised a jersey knit blend of about 21% polyester, about 65% nylon, and about 14% spandex having a weight per unit area of about 21% polyester, about 65% nylon, and about 14% spandex. Sample 8 had a 9.23% improvement in simulated lymphatic flow.
[0123] In Sample 9, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 1.0 g / cm 2 and the support layer 1300 has a stiffness (tested by ASTM D6828-02) of 12.2 grams force, an average thickness of 0.30 millimeters, a density of 0.43 g / cc, and a viscosity of 0.01 g / cm 3 . 2 The fabric comprised a 1×1 plain weave blend of about 65% polyester and about 35% cotton having a weight per unit area of about 1.02%. Sample 9 had a 10.45% improvement in simulated lymphatic flow.
[0124] In Sample 10, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 1.0 g / cm 2 and the support layer 1300 has a stiffness of 69.9 grams force (tested per ASTM D6828-02), an average thickness of 0.58 millimeters, a density of 0.47 g / cc, and a viscosity of 0.03 g / cm 3 . 2 The fabric comprised a 3×1 twill blend of about 65% polyester and about 35% cotton having a weight per unit area of about 1.28%. Sample 10 had a 22.27% improvement in simulated lymphatic flow.
[0125] In Sample 11, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 1220 grams force (tested per ASTM D6828-02), an average thickness of 0.93 millimeters, a density of 0.26 g / cc, and a viscosity of 0.02 g / cm 2 The samples included a 1×1 plain weave of polyurethane coated polyester having a weight per unit area of 1.001 g / m2. Sample 11 had a 38.38% improvement in simulated lymphatic flow.
[0126] In Sample 12, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 57.3 grams-force, an average thickness of 0.11 millimeters, a density of 1.14 g / cc, and a mass per unit area of 0.01 g / cm. 2 The samples included 8 gauge polyvinyl chloride film having a weight per unit area of 1.01 g / m. Sample 12 had a 4.56% improvement in simulated lymphatic flow.
[0127] In Sample 13, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2and the support layer 1300 is perforated with 6.35 millimeter openings having 25.4 millimeter center-to-center spacings, and has a stiffness of 840 grams force (tested per ASTM D6828-02), an average thickness of 0.30 millimeters, a density of 1.27 g / cc, and a mass per unit area of 0.04 g / cm. 2 The samples included 16 gauge polyvinyl chloride film having a weight per unit area of 1.01 g / m. Sample 13 had a 14.78% improvement in simulated lymphatic flow.
[0128] In Sample 14, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 1582 grams force, an average thickness of 0.37 millimeters, a density of 1.29 g / cc, and a mass per unit area of 0.05 g / cm. 2 The samples included 20 gauge polyvinyl chloride film having a weight per unit area of 1.01 g / m. Sample 14 had a 26.84% improvement in simulated lymphatic flow.
[0129] In Sample 15, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 1490 grams force, an average thickness of 0.23 millimeters, a density of 2.10 g / cc, and a mass per unit area of 0.05 g / cm. 2 The glass cloth was coated with polytetrafluoroethylene (PTFE) resin having a weight per unit area of 1.01 g / m. Sample 15 had a 42.09% improvement in simulated lymph flow.
[0130] In Sample 16, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 11486 grams force, an average thickness of 1.45 millimeters, a density of 0.82 g / cc, and a mass per unit area of 0.12 g / cm. 2 The glass cloth was coated with polytetrafluoroethylene (PTFE) resin having a weight per unit area of 1.01 g / m. Sample 16 had a 43.21% improvement in simulated lymphatic flow.
[0131] In Sample 17, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 2.28 grams force (tested per ASTM D6828-02), a stiffness of 222.75 grams force, an average thickness of 2.57 millimeters, a density of 0.08 g / cc, and a viscosity of 0.02 g / cm 2 Sample 17 had a 4.59% improvement in simulated lymphatic flow.
[0132] In Sample 18, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 0.02 g / cm 2 and a stiffness (tested by ASTM D6828-02) of 51.25 grams force, an average thickness of 0.33 millimeters, a density of 0.09 g / cc, and a viscosity of 0.0029 g / cm 3 . 2 Sample 18 had a 20.25% improvement in simulated lymphatic flow.
[0133] In Sample 19, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 1.0 g / cm 2 and a stiffness (tested by ASTM D6828-02) of 834.75 grams force, an average thickness of 0.37 millimeters, a density of 0.29 g / cc, and a viscosity of 0.01 g / cm 3 . 2The samples included a resorcinol formaldehyde latex coated glass mesh with a square grid having a weight per unit area of 1.025 g / m2. Sample 19 had a 31.21% improvement in simulated lymphatic flow.
[0134] In sample 20, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 359.5 grams force (tested per ASTM D6828-02), an average thickness of 2.50 millimeters, a density of 0.11 g / cc, and a viscosity of 0.03 g / cm 2 The samples included a non-woven polyester fabric having a square grid with a weight per unit area of 1.01 g / m2. Sample 20 had a 16.46% improvement in simulated lymphatic flow.
[0135] In Sample 21, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 comprises an open cell foam such as a reticulated polyurethane foam (e.g., GRANUFOAM™) having a weight per unit area of 0.02 g / cm 3 and a stiffness of 725 grams force (tested per ASTM D6828-02), an average thickness of 2.03 millimeters, a density of 0.10 g / cc, and a viscosity of 0.02 g / cm 3 . 2 The samples included a nonwoven polyester fabric having a weight per unit area of about 1.02% that was heat pressed at about 375 degrees Fahrenheit for one minute. Sample 21 had a 35.02% improvement in simulated lymphatic flow.
[0136] In Sample 22, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness (tested by ASTM D6828-02) of 282 grams force, an average thickness of 0.58 millimeters, a density of 1.53 g / cc, and a mass per unit area of 0.09 g / cm. 2 Sample 22 had an 8.44% improvement in simulated lymphatic flow.
[0137] In Sample 23, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2 and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness of 846 grams force (tested per ASTM D6828-02), an average thickness of 1.77 millimeters, a density of 0.98 g / cc, and a mass per unit area of 0.17 g / cm. 2 The acrylonitrile butadiene rubber had a weight per unit area of 1.01 g / m. Sample 23 had a 29.88% improvement in simulated lymphatic flow.
[0138] In Sample 24, the first manifold layer 405 had a stiffness of 910 grams force (tested per ASTM D6828-02), an average thickness of 6.35 millimeters, a density of 0.02 g / cc, and a viscosity of 0.02 g / cm 2and the support layer 1300 is perforated with 6.35 millimeter openings having a center-to-center spacing of 25.4 millimeters, and has a stiffness of 2326 grams-force (tested per ASTM D6828-02), an average thickness of 1.57 millimeters, a density of 1.53 g / cc, and a mass per unit area of 0.24 g / cm. 2 The acrylonitrile butadiene rubber had a weight per unit area of 1.01 g / m. Sample 24 had a 34.75% improvement in simulated lymphatic flow.
[0139] As shown in Figures 18A and 18B, improved performance occurred with stiffer outer layers. For example, dressing 110 samples 6, 11, 14, 15, 16, and 24, which have a support layer 1300 including a material with a stiffness greater than 1000 grams force (gf), provided improved simulated lymphatic flow rates of over 25%. Dressing 110 samples 6, 11, 15, 16, and 24, which have a support layer 1300 including a material with a stiffness greater than 1200 grams force (gf), provided improved simulated lymphatic flow rates of over 30%. Dressing 110 samples 6, 15, and 16, which have a support layer 1300 including a material with a stiffness greater than 1400 grams force (gf), provided improved simulated lymphatic flow rates of over 40%. For example, Sample 6 of the dressing 110, which includes a support layer 1300 including a material having a stiffness of 1446 grams-force (gf), provided an improvement in simulated lymph flow of about 44.30 percent. As shown in FIG. 18A and FIG. 18B, as the stiffness of the support layer 1300 increases, the simulated lymph flow generally increases. A range of about 42.09% to about 44.30% increase in simulated lymph flow was found when the stiffness of the support layer 1300 ranged from about 1446 grams-force to about 1490 grams-force (Samples 6 and 15). Above a certain threshold stiffness, the improvement in simulated lymph flow does not improve significantly. For example, Sample 16, which included a support layer 1300 having a stiffness of 11486 grams-force, did not provide an increase in simulated lymph flow over Sample 6, which included a support layer 1300 having a stiffness of 1446 grams-force. Furthermore, some samples with support layers 1300 having higher stiffness and higher weight per unit area did not perform as well as other samples with support layers 1300 having higher stiffness and lower weight per unit area. For example, a sample with a stiffness of 2326 grams force and a stiffness of 0.24 g / cm 2 Sample 24, which includes a support layer 1300 having a weight per unit area of 1,446 grams force and a stiffness of 0.02 g / cm 2The improvement rate of the simulated lymphatic flow was lower than that of Sample 6, which included a support layer 1300 having a weight per unit area of 100 mm or less. Thus, a support layer 1300 having a high weight per unit area may provide a lower improvement rate than a less stiff support layer 1300 having a lower weight per unit area.
[0140] 18, the size or density of the openings 1305 in the support layer 1300 did not appear to adversely affect the rate of improvement in simulated lymphatic flow. For example, Sample 6, having a support layer 1300 comprising neoprene foam perforated with approximately 6.35 millimeter openings 1305 with a center-to-center distance of approximately 25.4 millimeters, had a 44.30% improvement in simulated lymphatic flow. Furthermore, Sample 6, having a support layer 1300 comprising a composite film of glass cloth coated with polytetrafluoroethylene (PTFE) resin perforated with approximately 6.35 millimeter openings 1305 with a center-to-center distance of approximately 25.4 millimeters, had a 42.09% improvement in simulated lymphatic flow. In some embodiments, no reduction in improvement in simulated lymphatic flow was observed in a dressing 110 including a support layer 1300 having an array of openings 1305 circumferentially covering the first manifold layer 405 and having an open area of less than 50%.
[0141] Figure 19 is a bar graph of the data from Figure 18 with sample number along the x-axis and percent improvement along the y-axis. Figure 20 is a plot of performance data for an exemplary configuration of the dressing of Figure 13 using the test setup of Figure 16. In Figure 20, stiffness of the support layer 1300 is along the x-axis and percent improvement in lymphatic flow is along the y-axis. As shown in Figure 20, within the same type of material, the percent improvement in lymphatic flow increases approximately linearly with increasing stiffness, however, for different materials, the slopes are different.
[0142] The systems, devices, and methods described herein may provide significant advantages. For example, some embodiments of the dressing 110 may provide effective incision management while providing the additional benefit of negative pressure to the surrounding tissues, improving circulation through the subcutaneous lymphatic network, reducing edema, improving perfusion, and reducing the risk of postoperative complications such as infection, seroma, hematoma, and dehiscence. Some embodiments of the dressing 110 may be particularly effective for treating curved tissue sites, such as the chest, shoulder, arm, leg, knee, or ankle. The circumferential dressing 110 with the support layer 1300 may reduce swelling through improved local tissue decompression. More rapid and effective swelling reduction may be key to many clinical benefits. Furthermore, reduced pressure therapy provided by the dressing 110 may be adapted to current standard of care as an improvement to current rest, ice, compression, and elevation (RICE) protocols or other existing therapies.
[0143] While shown in several exemplary embodiments, those skilled in the art will recognize that the systems, devices, and methods described herein are susceptible to various changes and modifications that fall within the scope of the appended claims. Moreover, the description of various alternatives using terms such as "or" does not require mutual exclusivity unless clearly required by the context, and the definite article "a" or "an" does not limit the subject matter to a single example unless clearly required by the context. Components can also be combined or excluded in various configurations for purposes of sale, manufacture, assembly, or use. For example, in some configurations, the dressing 110, the container 115, or both can be excluded or separated from other components for manufacture or sale. In other exemplary configurations, the controller 130 can also be manufactured, constructed, assembled, or sold independently of other components.
[0144] The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from those known to those skilled in the art. Features, elements, and aspects described in the context of some embodiments may also be omitted, combined, or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention as defined by the appended claims.
Claims
1. 1. An apparatus for enhancing circulation through a subcutaneous lymphatic network at a tissue site, comprising: a manifold layer having a first stiffness, the manifold layer configured to be proximate to the tissue site; a support layer adjacent to the manifold layer, the support layer including one or more openings and having a second stiffness greater than the first stiffness; a cover adjacent to the support layer, the support layer being between the manifold layer and the cover; a fluid interface configured to fluidly couple at least one of the manifold layer and the support layer to a fluid conduit; when negative pressure is applied to one or more of the manifold layer and the support layer, the manifold layer collapses outwardly toward the support layer resulting in reduced pressure at the tissue site and increased lymphatic flow; When negative pressure is applied to one or more of the manifold layer and the support layer, at least a portion of the opening is visible through the cover. An apparatus comprising:
2. 2. The device of claim 1, wherein when negative pressure is applied to one or more of the manifold layer and the support layer, at least a portion of the cover is configured to be drawn into the one or more openings to form one or more recesses.
3. The apparatus of claim 1 or 2, wherein the second stiffness is at least 1.3 times greater than the first stiffness.
4. the manifold layer has a first thickness; the support layer has a second thickness less than the first thickness. An apparatus according to any one of claims 1 to 3.
5. The apparatus of any one of claims 1 to 4, wherein the manifold layer comprises a polymer foam, a polyurethane foam, an open cell foam, a reticulated foam, or a reticulated polyurethane foam.
6. The apparatus of any one of claims 1 to 5, wherein the first stiffness is between 800 grams force and 1000 grams force.
7. The apparatus of any one of claims 1 to 6, wherein the second stiffness is between 800 grams force and 3000 grams force.
8. The device of any one of claims 1 to 7, wherein the support layer comprises closed cell foam, neoprene foam, knitted fabric, woven fabric, polyvinyl chloride film, composite film, nonwoven fabric, or rubber.
9. 1. An apparatus for enhancing circulation through a subcutaneous lymphatic network at a tissue site, comprising: a manifold layer having a first stiffness between 800 g-force and 1000 g-force, the manifold layer configured to be positioned proximate to a tissue site; a support layer coupled to the manifold layer, the support layer including one or more openings and having a second stiffness between 1200 g-force and 1500 g-force; a cover coupled to the support layer, the support layer being between the manifold layer and the cover; when negative pressure is applied to the manifold layer, the manifold layer collapses toward the support layer, drawing the epidermis and underlying tissue of the tissue site outward; When negative pressure is applied to the manifold layer, at least a portion of the cover is configured to be drawn into the one or more openings to form one or more recesses. An apparatus comprising:
10. The apparatus of claim 9 , further comprising a fluid interface configured to fluidly couple at least one of the manifold layer and the support layer to a fluid conduit.
11. 10. The apparatus of claim 9, wherein at least a portion of the opening is visible through the cover when negative pressure is applied to one or more of the manifold layer and the support layer.
12. the manifold layer has a first thickness; the support layer has a second thickness less than the first thickness. Apparatus according to any one of claims 9 to 11.
13. The apparatus of any one of claims 9 to 12, wherein the manifold layer comprises a polymer foam, a polyurethane foam, an open cell foam, a reticulated foam, or a reticulated polyurethane foam.
14. The device of any one of claims 9 to 13, wherein the support layer comprises closed cell foam, neoprene foam, knitted fabric, woven fabric, polyvinyl chloride film, composite film, nonwoven fabric, or rubber.
15. The device of any one of claims 1 to 8, wherein the device is configured to form at least a partial wrap around the tissue site.
16. The apparatus of any one of claims 1 to 8 and 15, further comprising a bonding layer adjacent the manifold layer opposite the support layer.
17. The device of any one of claims 9 to 14, wherein the device is configured to form at least a partial wrap around the tissue site.
18. The apparatus of any one of claims 9 to 14 and 17, further comprising a bonding layer adjacent the manifold layer opposite the support layer.
Citation Information
Patent Citations
Wound treatment using reduced pressure
JP1997503923A
Wound treatment device using reduced pressure
JP2002541978A
System and method for wound healing using microelectromechanical systems (MEMS)
JP2012504460A
Reduced-pressure dressings, systems and methods employing desolidifying barrier layers
JP2014193395A
Reduced-pressure, composite manifolds
JP2016154929A
